Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5972885
SERIAL NO

08564161

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia is provided. The formulation comprises a highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOVITRUM ABSTOCKHOLM SE- 112 76

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Osterberg, Thomas Stockholm, SE 6 339
Spira, Jack Stockholm, SE 18 246
Widlund, Lars Sp.ang.nga, SE 2 143

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation